业绩总结 - 公司在2018年成功推出AlloCAR T™，并在不到3年的时间内实现领导地位，累计筹集资金15亿美元[4] - 目前已在75名患者中成功治疗AlloCAR T™，并控制了移植物抗宿主病(GvHD)和细胞排斥[4] - ALLO-501的初步数据表明，83%的总体反应率(ORR)和67%的完全反应率(CR)，与自体CAR T疗法相竞争[13] - ALLO-715在重度预处理和难治性患者中观察到60%的总体反应率（ORR）[24] - ALLO-715的MRD阴性率为100%（4/4）[26] 用户数据 - 安全人群中，患者的中位年龄为65岁，年龄范围为46至76岁[56] - 安全人群中，男性占61%，女性占39%[56] - 参与者中，94%的患者曾接受自体干细胞移植[56] 未来展望 - ALLO-501A的临床试验预计在2021年下半年启动，可能成为首个进入第二阶段的同种异体CAR T疗法[15] - 公司计划在2021年进行5项临床试验，包括首个关键试验和首个固体肿瘤试验[4] - ALLO-316在肾细胞癌（RCC）中的I期TRAVERSE试验计划于2021年上半年开始[37] 新产品和新技术研发 - ALLO-715的细胞持久性在4个月内得到观察[24] - ALLO-647的开发旨在增强同种异体CAR T产品候选药物的扩展和持久性[8] - ALLO-647的疗效和持久性正在持续评估，目标是增强多发性骨髓瘤患者的治疗效果[64] 市场扩张和并购 - Allogene Overland Biopharm合资企业获得1.17亿美元的非稀释资本支持[40] - Newark设施预计在2021年开始生产，旨在支持临床和商业制造[10] 负面信息 - ALLO-715的CRS发生率为45%，无3级或以上的CRS[25] - ALLO-715的3级或以上中性粒细胞减少症发生率为52%[25] 其他新策略和有价值的信息 - 公司在制造和测试方面的所有权有助于提高过程优化和监管合规性[9] - 研究显示，细胞扩增在治疗后7天内可观察到，且高剂量患者的扩增效果更佳[59] - ALLO-501的中位反应时间为16天，随着细胞剂量的增加，反应率逐渐提高[58]

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2020 Earnings Conference Call November 4, 2020 8:30 AM ET Company Participants Christine Cassiano – Chief Communications Officer David Chang – President and Chief Executive Officer Rafael Amado – Executive Vice President-Research and Development and Chief Medical Officer Eric Schmidt – Chief Financial Officer Conference Call Participants Marc Frahm – Cowen Salveen Richter – Goldman Sachs Brian Ayman – Jefferies Tyler Van Buren – Piper Sandler John Newman – Canacc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________________ FORM 10-Q ________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2020 Earnings Conference Call August 5, 2020 8:30 AM ET Company Participants Christine Cassiano – Chief Communications Officer David Chang – President and Chief Executive Officer Rafael Amado – Executive Vice President-Research and Development and Chief Medical Officer Eric Schmidt – Chief Financial Officer Conference Call Participants Phil Nadeau – Cowen and Company Andrea Tan – Goldman Sachs Biren Amin – Jefferies Gavin Scott – JPMorgan Tyler Van Buren – Piper ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________________ FORM 10-Q ________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 ...